GO:0043569 negative regulation of insulin-like growth factor receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043569 describes any process that stops, prevents, or reduces the frequency, rate or extent of insulin-like growth factor receptor (IGF1R) signaling.
• Negative regulation of IGF1R signaling is essential for balancing growth, metabolism, and longevity, and its dysregulation is linked to cancer, fibrosis, and metabolic disease [3,4,7].
• Key negative regulators include proteasome-mediated degradation of IRS-2, phosphatases, and feedback loops that fine-tune IGF1R output.
• IGF1R pathway blockade is an active clinical strategy in oncology, with multiple drugs targeting the receptor or its ligands.
• Experimental models such as knockout, point-mutation, and overexpression cell lines are critical for dissecting negative regulation of IGF1R signaling [3,6].
• CRISPR-based screens and bioinformatics can identify novel negative regulators of IGF1R signaling for therapeutic development.
Description
The insulin-like growth factor receptor (IGF1R) signaling pathway is a central regulator of cell growth, survival, and metabolism. Its activity must be tightly controlled to prevent excessive proliferation and oncogenic transformation. GO:0043569, negative regulation of insulin-like growth factor receptor signaling pathway, encompasses the diverse molecular mechanisms that attenuate or terminate IGF1R signaling [3,6]. Understanding these negative regulatory processes is crucial for researchers studying cancer, metabolic disorders, and aging, as restoring proper inhibition of IGF1R signaling can suppress tumor growth and improve healthspan [3,7]. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a comprehensive overview of the mechanisms, key genes, and research methods associated with GO:0043569.
negative regulation of insulin-like growth factor receptor signaling pathway At A Glance
| GO ID | GO:0043569 |
|---|---|
| GO term | negative regulation of insulin-like growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | inhibition of insulin-like growth factor receptor signaling pathway; negative regulation of IGF receptor signaling pathway |
| Major function | Attenuation or termination of IGF1R-mediated signal transduction |
| Related pathways | Insulin/IGF signaling, PI3K-AKT, MAPK, proteasomal degradation |
| Cellular location | Plasma membrane, cytoplasm, endosomes, proteasome |
| Key regulators | IRS-2, phosphatases, SOCS proteins, ubiquitin ligases |
What Is GO:0043569?
GO:0043569 refers to any biological process that stops, prevents, or reduces the frequency, rate, or extent of insulin-like growth factor receptor signaling. This includes mechanisms such as receptor downregulation, degradation of signaling intermediates, and activation of negative feedback loops that collectively dampen the cellular response to IGF1 and IGF2 [3,6].
Why Is negative regulation of insulin-like growth factor receptor signaling pathway Important in Cell Biology?
Negative regulation of IGF1R signaling is critical for maintaining tissue homeostasis and preventing pathological growth. Dysregulation of this process contributes to cancer progression, fibrosis, and metabolic syndromes, making it a prime target for therapeutic intervention [3,4,7].
• Prevents uncontrolled cell proliferation and tumorigenesis.
• Modulates longevity and healthspan through fine-tuning of IGF1R signaling.
• Influences hepatic stellate cell activation and liver fibrosis.
• Regulates bone metabolism and autophagy in skeletal tissues.
• Protects against intestinal injury and inflammation.
• Controls prostate cancer cell exosome composition and signaling.
• Affects triple-negative breast cancer metastasis via m6A reader IGF2BP3.
• Provides targets for IGF1R pathway blockade in clinical oncology.
• Balances insulin sensitivity and glucose homeostasis.
• Serves as a model for studying feedback regulation in receptor tyrosine kinase pathways.
What Happens During negative regulation of insulin-like growth factor receptor signaling pathway?
Receptor Downregulation and Degradation
In simple terms: The cell removes IGF1 receptors from its surface to stop receiving growth signals.
Negative regulation of IGF1R signaling often begins with ligand-induced internalization and subsequent degradation of the receptor. Ubiquitination of IGF1R by E3 ligases targets it for lysosomal or proteasomal degradation, reducing the number of receptors available to bind IGF1 or IGF2. This process is essential for terminating signaling after ligand stimulation and preventing sustained activation.
Proteasome-Mediated Degradation of IRS-2
In simple terms: The cell destroys a key adaptor protein, IRS-2, to shut down the signal from the receptor.
Insulin receptor substrate-2 (IRS-2) is a critical adaptor that transmits signals from IGF1R to downstream pathways. Proteasome-mediated degradation of IRS-2, triggered by prolonged insulin/IGF1 exposure, represents a major negative feedback mechanism. This degradation reduces the availability of IRS-2 for receptor binding and attenuates PI3K-AKT signaling.
Phosphatase-Mediated Inactivation
In simple terms: Enzymes called phosphatases remove phosphate groups from signaling proteins to turn off the signal.
Protein tyrosine phosphatases (PTPs) such as PTP1B and PTEN can dephosphorylate key components of the IGF1R pathway, including the receptor itself and IRS proteins. This dephosphorylation reverses activating phosphorylations and serves as a rapid negative regulatory mechanism [3,7].
Feedback Inhibition by SOCS Proteins
In simple terms: SOCS proteins act as brakes on the signaling pathway by targeting components for degradation.
Suppressor of cytokine signaling (SOCS) proteins, particularly SOCS1 and SOCS3, can bind to IGF1R or its substrates and recruit ubiquitin ligases, leading to degradation of signaling intermediates. This feedback inhibition is important for preventing excessive signaling in response to growth factors.
Autophagy-Mediated Regulation
In simple terms: Autophagy, the cell's recycling system, can degrade signaling proteins to limit IGF1R activity.
Recent studies have highlighted the role of autophagy in degrading components of the IGF1R pathway. Autophagy-related proteins can target IRS-1 and other signaling molecules for lysosomal degradation, thereby contributing to negative regulation of IGF1R signaling. This crosstalk is particularly relevant in bone metabolism and metabolic tissues.
Key Genes Involved in GO:0043569 negative regulation of insulin-like growth factor receptor signaling pathway
The following genes and proteins are key players in the negative regulation of IGF1R signaling, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IGF1R | Receptor tyrosine kinase; target of negative regulation | Central to pathway; mutations affect signaling strength [3,7] |
| IRS2 | Adaptor protein; degraded by proteasome to attenuate signaling | Key node for feedback inhibition |
| PTPN1 | Protein tyrosine phosphatase; dephosphorylates IGF1R and IRS | Negative regulator; drug target for diabetes and cancer |
| PTEN | Lipid phosphatase; opposes PI3K-AKT signaling | Tumor suppressor; frequently mutated in cancers |
| SOCS1 | Suppressor of cytokine signaling; promotes degradation of signaling intermediates | Feedback inhibitor; modulates immune and growth signaling |
| SOCS3 | Suppressor of cytokine signaling; attenuates IGF1R signaling | Involved in metabolic and inflammatory pathways |
| NINJ2 | Hepatocyte protein; promotes HSC activation via IGF1R/EGR1/PDGF-BB | Linked to liver fibrosis; potential therapeutic target |
| IGF2BP3 | m6A reader; promotes TNBC metastasis via HOXB9-IL15RA | Oncogenic; modulates IGF signaling in breast cancer |
| SRC | Non-receptor tyrosine kinase; enriched in exosomes | Modulates IGF1R signaling in prostate cancer |
| GRK | G-protein-coupled receptor kinases; interact with IGF1R | Regulate receptor trafficking and signaling |
| FAK | Focal adhesion kinase; crosstalk with IGF1R | Influences cell migration and survival |
| BECN1 | Autophagy regulator; affects degradation of signaling proteins | Links autophagy to IGF1R regulation |
| MAP1LC3B | Autophagosome marker; involved in degradation of IRS proteins | Readout for autophagy-mediated negative regulation |
| AKT1 | Downstream kinase; inhibited by negative regulators | Effector of IGF1R signaling; target of feedback |
| MAPK1 | Downstream kinase; modulated by negative regulators | Effector of IGF1R signaling |
| FOXO | Transcription factor; inhibited by AKT downstream of IGF1R | Mediates longevity and stress responses |
| MTOR | Kinase; integrates IGF1R signals with nutrient sensing | Central to feedback regulation |
| IGF1 | Ligand; binding triggers receptor activation and subsequent negative feedback | Therapeutic target in cancer and growth disorders |
How Is negative regulation of insulin-like growth factor receptor signaling pathway Regulated?
Negative regulation of IGF1R signaling is itself tightly regulated by multiple feedback loops. mTOR, a downstream kinase, can exert negative feedback on IGF1R through S6K-mediated phosphorylation of IRS-1, leading to its degradation. Additionally, the integrated stress response (ISR) can modulate IGF1R signaling under conditions of cellular stress. Autophagy also plays a role in degrading pathway components, as seen in bone metabolism. These regulatory layers ensure that IGF1R signaling is appropriately attenuated in response to environmental cues.
negative regulation of insulin-like growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IGF1R | Cancer, growth disorders | Knockout and point-mutation cell lines; xenograft models |
| IRS2 | Type 2 diabetes, insulin resistance | IRS2 knockout and overexpression models |
| NINJ2 | Liver fibrosis | Hepatocyte-specific knockout or overexpression |
| IGF2BP3 | Triple-negative breast cancer metastasis | Knockdown and overexpression in TNBC cell lines |
| PTEN | Cancer, metabolic syndrome | PTEN knockout and knock-in models |
Cancer
Loss of negative regulation of IGF1R signaling is a hallmark of many cancers. Overexpression of IGF1R or its ligands, or mutations that impair negative feedback, lead to uncontrolled proliferation and survival. IGF1R pathway blockade is a clinical strategy in oncology, with monoclonal antibodies and tyrosine kinase inhibitors under investigation. In triple-negative breast cancer, the m6A reader IGF2BP3 promotes metastasis through the HOXB9-IL15RA pathway, highlighting the complexity of IGF signaling in cancer.
Liver Fibrosis
Hepatocyte Ninjurin2 (NINJ2) promotes hepatic stellate cell activation and liver fibrosis through the IGF1R/EGR1/PDGF-BB signaling pathway. Negative regulation of IGF1R signaling may therefore be protective against fibrosis progression.
Metabolic Disorders
Dysregulation of IGF1R signaling contributes to insulin resistance and type 2 diabetes. Proteasome-mediated degradation of IRS-2 is a key negative feedback mechanism that can be impaired in metabolic disease, leading to hyperinsulinemia and altered glucose homeostasis.
Aging and Longevity
Fine-tuning cardiac IGF1R signaling is associated with health and longevity. Reduced IGF1R signaling extends lifespan in model organisms, and negative regulators of this pathway are potential targets for geroprotective interventions.
From negative regulation of insulin-like growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IGF1R signaling? | Knockout cell line (e.g., CRISPR-Cas9) followed by IGF1 stimulation and pathway readouts |
| Does a specific point mutation in IGF1R affect negative regulation? | Point-mutation knock-in cell line |
| Does overexpression of a candidate negative regulator suppress tumor growth? | Overexpression cell line and xenograft models |
| How does a tagged negative regulator localize and interact? | Tagged knock-in (e.g., GFP, HA) for imaging and co-IP |
| What is the role of autophagy in IGF1R degradation? | Autophagy-related gene knockout and overexpression models |
| Can CRISPR library screening identify novel negative regulators? | Genome-wide CRISPR knockout library screening with IGF1R signaling reporter |
How to Study the negative regulation of insulin-like growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene essentiality and pathway activity | Identify novel negative regulators |
| Phosphoproteomics | Global phosphorylation changes | Map signaling nodes affected by negative regulators |
| RNA-seq | Transcriptomic changes | Uncover feedback gene expression programs |
| Western blot | Protein levels and phosphorylation | Validate specific pathway components |
| Co-immunoprecipitation | Protein-protein interactions | Detect complexes involving IGF1R and regulators |
| Proximity ligation assay | In situ protein interactions | Visualize receptor-regulator complexes |
| Autophagy flux assay | Autophagic degradation | Assess role of autophagy in IGF1R turnover |
| Luciferase reporter assay | Transcriptional activity | Measure downstream pathway output |
CRISPR-Cas9 Knockout Screening
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses IGF1R signaling. Cells are transduced with a lentiviral sgRNA library, selected, and analyzed for pathway activity using reporters or phospho-specific antibodies. This approach has been used to uncover novel negative regulators of receptor tyrosine kinase pathways.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics allows global profiling of phosphorylation events downstream of IGF1R. By comparing control and knockout cells, researchers can identify specific phosphorylation sites that are regulated by candidate negative regulators.
RNA Sequencing (RNA-seq)
RNA-seq measures transcriptomic changes upon manipulation of negative regulators. It can reveal feedback mechanisms and gene expression signatures associated with IGF1R signaling attenuation.
Proximity Ligation Assay (PLA) and Imaging
PLA and immunofluorescence imaging can visualize interactions between IGF1R and its negative regulators at the single-cell level. This is useful for studying receptor internalization and degradation dynamics.
How CRISPR Can Be Used to Study GO:0043569 negative regulation of insulin-like growth factor receptor signaling pathway
Knockout
CRISPR-Cas9 knockout of candidate negative regulators (e.g., PTPN1, PTEN, SOCS1) can be used to assess their role in IGF1R signaling. Loss of function typically leads to enhanced pathway activity, which can be measured by increased phosphorylation of IGF1R, AKT, and MAPK.
Point Mutation
Point mutations in IGF1R or its substrates can mimic clinical variants or disrupt specific phosphorylation sites. For example, knock-in of a tyrosine-to-phenylalanine mutation in IRS-2 can prevent its degradation, leading to sustained signaling.
Knock-in
Knock-in of tagged versions of negative regulators (e.g., GFP-tagged SOCS1) allows real-time imaging and interaction studies. This approach helps track protein localization and dynamics during IGF1R signaling.
Overexpression
Overexpression of negative regulators using CRISPR activation (CRISPRa) or lentiviral vectors can suppress IGF1R signaling and reduce tumor growth in xenograft models. This is useful for validating tumor suppressor functions.
How EDITGENE Supports negative regulation of insulin-like growth factor receptor signaling pathway Research
Researchers studying negative regulation of insulin-like growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway attenuation. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of insulin-like growth factor receptor signaling pathway research.
Frequently Asked Questions About negative regulation of insulin-like growth factor receptor signaling pathway
What is GO:0043569?
GO:0043569 is the Gene Ontology term for negative regulation of insulin-like growth factor receptor signaling pathway, describing any process that stops, prevents, or reduces IGF1R signaling.
What genes are involved in negative regulation of IGF1R signaling?
Key genes include IRS2, PTPN1, PTEN, SOCS1, SOCS3, and NINJ2, among others [3,4,6].
How is IGF1R signaling negatively regulated?
Mechanisms include receptor downregulation, proteasomal degradation of IRS-2, phosphatase-mediated inactivation, and feedback inhibition by SOCS proteins [3,6].
Why is negative regulation of IGF1R signaling important in cancer?
Loss of negative regulation leads to uncontrolled proliferation and survival, making it a target for cancer therapy.
What diseases are associated with dysregulated IGF1R negative regulation?
Cancer, liver fibrosis, metabolic disorders, and aging-related conditions [3,4,6,7].
What experimental models are used to study GO:0043569?
Knockout, point-mutation, knock-in, and overexpression cell lines, as well as CRISPR library screens [6,7].
How does autophagy contribute to negative regulation of IGF1R signaling?
Autophagy degrades signaling components like IRS-1, thereby attenuating IGF1R signaling.
What is the role of IRS-2 in IGF1R negative regulation?
IRS-2 is an adaptor protein whose proteasome-mediated degradation reduces downstream signaling.
Can CRISPR screening identify new negative regulators of IGF1R?
Yes, genome-wide CRISPR knockout screens can uncover novel genes that negatively regulate IGF1R signaling.
What services does EDITGENE offer for studying GO:0043569?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services.
Conclusion
Negative regulation of insulin-like growth factor receptor signaling pathway (GO:0043569) is a vital process that maintains cellular homeostasis and prevents pathological growth. Dysregulation of this process is implicated in cancer, fibrosis, metabolic disorders, and aging. Advances in CRISPR-based models and screening technologies are accelerating the discovery of novel negative regulators and therapeutic targets. EDITGENE's comprehensive services support researchers in dissecting these mechanisms and translating findings into clinical applications.
References
- 1. Wang J et al.. 2023. The role of autophagy in bone metabolism and clinical significance.. Autophagy 19(9):2409-2427 PMID: 36858962
- 3. Abdellatif M et al.. 2022. Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity.. Circulation 145(25):1853-1866 PMID: 35616058
- 4. Wang Y et al.. 2023. Hepatocyte Ninjurin2 promotes hepatic stellate cell activation and liver fibrosis through the IGF1R/EGR1/PDGF-BB signaling pathway.. Metabolism 140:155380 PMID: 36549436
- 5. Zhang X et al.. 2026. The m6A reader IGF2BP3 promotes triple-negative breast cancer metastasis through HOXB9-IL15RA pathway.. Funct Integr Genomics 26(1) PMID: 42168464
- 6. Rui L et al.. 2001. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2.. J Biol Chem 276(43):40362-7 PMID: 11546773
- 7. Iams WT et al.. 2015. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.. Clin Cancer Res 21(19):4270-7 PMID: 26429980
- 8. DeRita RM et al.. 2017. c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes.. J Cell Biochem 118(1):66-73 PMID: 27232975
